News
-
Brigham and Women’s Hospital (BWH) has announced an upcoming clinical trial of an intranasal vaccine for the prevention and treatment of Alzheimer’s disease (AD). The SAD trial is expected to enroll 16 early-staged Alzheimer’s patients aged… Read more . . .
-
According to Inhalation Sciences (ISAB), Akari Therapeutics has chosen ISAB’s CRO, Inhalation Research Services, to conduct a pharmacokinetic study of Akari’s Nomacopan, a C5 and LTB4 inhibitor that the company is evaluating as an inhaled… Read more . . .
-
Padagis (formerly Perrigo’s generic prescription pharmaceutical business) has announced the launch of its generic version of Zomig zolmitriptan nasal spray for the treatment of migraine headaches in patients aged 12 and older. Altaris acquired Padagis… Read more . . .
-
CDMO Hovione said that it is investing $170 million to increase overall capacity at its manufacturing facilities in Portugal, Ireland, and the US by about 25% to meet strong demand. According to the company, its… Read more . . .
-
For the second year, the Drug Delivery to the Lungs conference will take place virtually as a result of the COVID-19 pandemic. The conference will include both live and recorded scientific presentations, live discussion sessions,… Read more . . .
-
Pneumagen has announced the initiation of a Phase 1 SAD/MAD study of its Neumifil carbohydrate binding module (mCBM) nasal spray, which the company is developing for the prevention and treatment of viral respiratory infections. The… Read more . . .
-
Birmingham Biotech said that it has licensed a carrageenan/gellan antiviral nasal spray from the University of Birmingham and intends to market the spray in the UK and in Asian countries for protection against COVID-19 starting… Read more . . .
-
According to Pulmatrix, a dispute between Pulmatrix and Cipla over funding related to the development of Pulmazole intraconazole DPI (PUR 1900) has been resolved. In May 2021, Pulmatrix announced that Cipla had failed to provide… Read more . . .
-
According to Liquidia, the FDA has tentatively approved the company’s NDA for its Yutrepia (LIQ861) treprostinil DPI for the treatment of pulmonary arterial hypertension (PAH). The FDA had previously issued a complete response letter to… Read more . . .
-
According to EffRx Pharmaceuticals, Swissmedic has approved Bronchitol inhaled dry powder mannitol as an add-on to other medications for the treatment of cystic fibrosis in patients 6 years old and older. EffRx acquired Swiss rights… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden